Evidence map›Paper›PMID 42654108›Full record

ReviewPharmaceutics2026

Lipid Nanoparticles for Gene Therapy: Unresolved Challenges in Manufacturing, Transdermal Delivery, Machine Learning, Endosomal Escape, and the Protein Corona.

Ognjen Milić, Sanela M Savić, Melanija Zurković, Boban Stanojević, Snežana Savić

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ognjen MilićDepartment of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, 11221 Belgrade, Serbia.ORCID 0009-0008-9512-6277
Sanela M SavićFaculty of Technology in Leskovac, University of Niš, 16000 Leskovac, Serbia.ORCID 0000-0002-8121-6924
Melanija ZurkovićDepartment of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, 11221 Belgrade, Serbia.ORCID 0009-0008-0180-8139
Boban StanojevićDepartment of Pharmacology, Faculty of Pharmacy, University of Belgrade, 11221 Belgrade, Serbia.
Snežana SavićDepartment of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, 11221 Belgrade, Serbia.ORCID 0000-0002-6236-9730

Funding

Ministry of Science, Technological Development, and Innovation Grant agreements with the University of Belgrade-Faculty of Pharmacy, Nos. 451-03-33/2026-03/200161 and 451-03-34/2026-03/200161Science Fund of the Republic of Serbia MiNe2Brain research project, Grant No. 17811, within the DIASPORA 2023 program
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) are now the leading delivery platform for nucleic acid therapeutics, but progress in the field is measured almost entirely by physicochemical and computational proxies rather than by functional properties that determine therapeutic outcomes. This review examines six interconnected areas of LNP development: microfluidic manufacturing, lyophilization, transdermal microneedle delivery, machine learning-guided formulation design, endosomal escape biology, and protein corona-mediated organ targeting. Although these areas are often discussed separately, they are linked by a common gap between routinely measured physicochemical or computational endpoints and the biological outcomes that determine therapeutic performance. A recently developed antifouling coating substantially reduced microfluidic channel fouling under the tested conditions, although its scalability remains to be validated. Lyophilization, by contrast, still requires formulation specific re-optimization for each new lipid composition, which remains an important barrier to clinical translation. In microneedle-based delivery, physicochemical integrity after fabrication is routinely treated as a proxy for therapeutic function, although, to our knowledge, no published study has directly compared endosomal escape capacity before and after microneedle fabrication. In machine learning, model accuracy is limited primarily by fragmented, outcome-biased training data rather than by algorithm design. Independent measurements of endosomal escape efficiency converge on a low ceiling whose biological origin, whether lipid-specific or inherent to the mechanism, remains unknown. For organ-selective targeting, one mechanistic account rests on a hypothesis tested in advance; another, equally prominent, has not been shown to have been anticipated rather than reconstructed after the fact. Closing this gap is now the field's central methodologically priority.

Indexed as

endosomal escapeformulation optimizationionizable lipidslipid nanoparticlesmachine learningmicrofluidicsmicroneedlemRNA delivery

Identifiers

PMID42654108
PMCPMC13516193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.